Brimonidine tartrate is under clinical development by Visiox Pharma and currently in Pre-Registration for Open-Angle Glaucoma. According to GlobalData, Pre-Registration drugs for Open-Angle Glaucoma have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Brimonidine tartrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Brimonidine tartrate overview
Brimonidine tartrate is under development for the treatment of open-angle glaucoma and ocular hypertension. It is formulated as ophthalmic solution administered once a day (OD) as eye drops. The drug candidate targets alpha 2 adrenergic receptor. It is developed based on TearAct technology. The technology involves drug-resin complex suspension which provides slow, consistent and sustained exposure.
Visiox Pharma overview
Visiox Pharma (Visiox) is focused on developing ophthalmic drugs. Visiox is headquartered in the US.
For a complete picture of Brimonidine tartrate’s drug-specific PTSR and LoA scores, buy the report here.